Evaluation of safety and efficacy of Unani Add-on regimen in preventing the progression of severity of the disease in hospitalized SARS-CoV2 tested positive asymptomatic /mild to moderate symptomatic COVID-19 cases- A Randomised Controlled Clinical Trial

Authors

  • Asim Ali Khan Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Naseem Akhtar Ayurvedic and Unani Tibbiya College & Hospital (AUTCH), New Delhi
  • Naheed Parveen Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Pradeep Kumar Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Ghazala Javed Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Pawan Kumar Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Rampratap Meena Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Jamal Akhtar Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Nighat Anjum Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Usama Akram Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Nauman Saleem Ayurvedic and Unani Tibbiya College & Hospital (AUTCH), New Delhi
  • Tamanna Nazli Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Anirban Rej Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India
  • Shoeb Mumtaz Central Council for Research in Unani Medicine, Ministry of AYUSH, Government of India

DOI:

https://doi.org/10.3329/bjms.v21i4.60290

Keywords:

COVID-19; Immunity; Quality of life; Randomized Controlled Trial; WHO QoL; RT-PCR

Abstract

Objectives: The study aimed to establish the effectiveness of Unani add-on regimen by comparing theduration required for change in disease status from COVID-19 positive asymptomatic / mildto moderate symptomatic patients to asymptomatic negative.

Methods: This single-centric, randomized, twin arm, controlled, clinical trial was carried out on a totalnumber of 62 RT-PCR confirmed COVID-19 patients. The Intervention group (IG) receivedUnani Regimen (Khameera Marwareed and Unani Joshanda) in addition to the conventional management, while the Control group (CG) received only conventional management.

Results: It was observed that 16 (51.6%) patients in Intervention Group and 3 (9.4%) patients incontrol group became negative for COVID-19 at day 7 and remaining 13 out of 15 (93.5%) patients in Intervention Group and 20 out of 28 (74.1%) patients in control group becamenegative for COVID-19 at day 14 .This effect of the Unani Regimen in comparison to thecontrol group was statistically significant (p =0.003).

Conclusions: It can be concluded that the change of COVID-19 positive asymptomatic / mild to moderate symptomatic patients to RT-PCR negative was much earlier in the add-on Unani regimen group as compared to control group.

Bangladesh Journal of Medical Science Vol. 21 No. 04 October’22 Page : 901-911

Downloads

Download data is not yet available.
Abstract
281
PDF
325

Downloads

Published

2022-09-11

How to Cite

Khan, A. A. ., Akhtar, N. ., Parveen, N. ., Kumar, P. ., Javed, G. ., Kumar, P. ., Meena, R. ., Akhtar, J. ., Anjum, N. ., Akram, U. ., Saleem, N. ., Nazli, T. ., Rej, A. ., & Mumtaz, S. . (2022). Evaluation of safety and efficacy of Unani Add-on regimen in preventing the progression of severity of the disease in hospitalized SARS-CoV2 tested positive asymptomatic /mild to moderate symptomatic COVID-19 cases- A Randomised Controlled Clinical Trial. Bangladesh Journal of Medical Science, 21(4), 901–911. https://doi.org/10.3329/bjms.v21i4.60290

Issue

Vol. 21 No. 4 (2022)

Section

Original Articles

License

Copyright (c) 2022 Asim Ali Khan, Naseem Akhtar, Naheed Parveen, Pradeep Kumar, Ghazala Javed, Pawan Kumar, Rampratap Meena, Jamal Akhtar, Nighat Anjum, Usama Akram, Nauman Saleem, Tamanna Nazli, Anirban Rej, Shoeb Mumtaz

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:

  1. Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.

  2. Creative Commons Licence
    Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.